For investors
Lexi Ventures invests in early stage gene tech companies.
This focus is rooted in these beliefs.
Genetic engineering will change the lives of all people to a degree comparable with electricity, the internet, and artificial intelligence.
This will enable startups to create unmatched opportunities for wealth creation for their customers, employees, and investors.
The convergence of protein modeling, harnessing CRISPR, falling costs, and growing talent has made this the right time for the thesis.
There is more alpha in gene tech than other biotech businesses.
Gene tech startups aim to cure many of the worst and most expensive diseases, improving happiness and reducing healthcare needs. Other gene tech startups will enable plants and microbes to produce newer and better things while sustaining the natural environment.
Lexi Ventures seeks to build a venture capital investment portfolio concentrated in gene tech companies from their early stages.
For startups
Lexi Ventures provides seed stage funding for startups applying or enabling genomics or synthetic biology.
Most investments that Lexi Ventures considers are best described using the key words DNA, RNA, proteins, or cells.
Lexi Ventures exclusively considers companies with a US corporate structure, and usually companies headquartered in the US.
Lexi Ventures occasionally considers pre-seed funding rounds of particularly promising companies and post-seed rounds with particularly attractive terms.
Please connect if you are working on any of these.
Cell and gene therapies
Diagnostics using DNA, RNA, or proteins
Engineered vaccines
Probiotic cosmetics
Cultured food proteins
Genetically optimized seeds or fertilizers
Microbial processing of materials or chemicals
Software, data, chemistry, devices, processes, or IP supporting any of the above
With great respect to companies and entrepreneurs in adjacent tech, Lexi Ventures does not invest in:
Small molecule pharmaceuticals
Medical devices not related to gene tech
Virtual healthcare software
Agriculture, mining, or manufacturing that is not advantaged by the engineering of plants or microbes
Jonah Probell
Managing Partner
Jonah manages the investments for Lexi Ventures. Prior to finance, he held engineering, executive, and founder roles in 7 startups. He achieved 2 IPOs, 16 granted patents and wrote 2 books.
Jonah believe in a rational, dispassionate, methodical approach to investing for maximum realized IRR. This approach grew from a decade of experience building patent portfolios.
Jonah has a lifelong interest in science, engineering, economics, philosophy, and the history of human technological development.